Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Daniel, Sikorski"'
Autor:
Jennifer Gantchev, Julia Messina-Pacheco, Amelia Martínez Villarreal, Brandon Ramchatesingh, Philippe Lefrançois, Pingxing Xie, Laetitia Amar, Hong Hao Xu, Keerthenan Raveendra, Daniel Sikorski, Daniel Josue Guerra Ordaz, Raman Preet Kaur Gill, Marine Lambert, Ivan V. Litvinov
Publikováno v:
Cells, Vol 12, Iss 12, p 1627 (2023)
Genomic instability is a prominent hallmark of cancer, however the mechanisms that drive and sustain this process remain elusive. Research demonstrates that numerous cancers with increased levels of genomic instability ectopically express meiosis-spe
Externí odkaz:
https://doaj.org/article/41b9886295ff42c897df066097caad17
Autor:
Litvinov, Jennifer Gantchev, Julia Messina-Pacheco, Amelia Martínez Villarreal, Brandon Ramchatesingh, Philippe Lefrançois, Pingxing Xie, Laetitia Amar, Hong Hao Xu, Keerthenan Raveendra, Daniel Sikorski, Daniel Josue Guerra Ordaz, Raman Preet Kaur Gill, Marine Lambert, Ivan V.
Publikováno v:
Cells; Volume 12; Issue 12; Pages: 1627
Genomic instability is a prominent hallmark of cancer, however the mechanisms that drive and sustain this process remain elusive. Research demonstrates that numerous cancers with increased levels of genomic instability ectopically express meiosis-spe
Autor:
Sarah, Zhou, Sriraam, Sivachandran, Daniel, Sikorski, Hong Hao, Xu, François, Lagacé, Joël, Claveau, Thomas G, Salopek, Robert, Gniadecki, Ivan V, Litvinov
Publikováno v:
Journal of cutaneous medicine and surgery. 26(2)
Autor:
Stephanie Ghazal, Thomas G. Salopek, Ivan V. Litvinov, Marcus O. Butler, Honghao Xu, Sarah Zhou, Joël Claveau, May Chergui, Daniel Sikorski, Carolyn Nessim, Wilson H. Miller, Andrei Zubarev, Margaret Redpath, François Lagacé, Robert Gniadecki, Teresa M. Petrella
Publikováno v:
Cancers
Cancers, Vol 13, Iss 2282, p 2282 (2021)
Cancers, Vol 13, Iss 2282, p 2282 (2021)
Simple Summary Reflex molecular testing is an emerging concept in oncology that, for a variety of cancers, was demonstrated to reduce the time to treatment initiation, thus potentially impacting survival outcomes. In advanced melanoma, BRAF mutation